Cargando…

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy

BACKGROUND: Combining in vitro mouth–throat deposition measurements, cascade impactor data and computational fluid dynamics (CFD) simulations, four different inhalers were compared which are indicated for chronic obstructive pulmonary disease (COPD) treatment. METHODS: The Respimat inhaler, the Bree...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciciliani, Anna-Maria, Langguth, Peter, Wachtel, Herbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457178/ https://www.ncbi.nlm.nih.gov/pubmed/28603412 http://dx.doi.org/10.2147/COPD.S115886

Ejemplares similares

Reduced Environmental Impact of the Reusable Respimat(®) Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers
por: Hänsel, Michaela, et al.
Publicado: (2019)

In Vitro Determination of Respimat(®) Dose Delivery in Children: An Evaluation Based on Inhalation Flow Profiles and Mouth–Throat Models
por: Bickmann, Deborah, et al.
Publicado: (2016)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers
por: W. H. Kocks, Janwillem, et al.
Publicado: (2022)

Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
por: Dhand, Rajiv, et al.
Publicado: (2019)

A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
por: Kamin, Wolfgang, et al.
Publicado: (2015)

Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD
por: Svedsater, Henrik, et al.
Publicado: (2013)

In Vitro Dosing Performance of the ELLIPTA(®) Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™)
por: Hamilton, Melanie, et al.
Publicado: (2015)

Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD
por: Crim, Courtney, et al.
Publicado: (2019)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

Feedback systems in multi-dose dry powder inhalers
por: Emeryk, Andrzej, et al.
Publicado: (2022)

Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD
por: Chapman, Kenneth R, et al.
Publicado: (2011)

Patients’ usability of seven most used dry-powder inhalers in COPD
por: Dal Negro, Roberto W., et al.
Publicado: (2019)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
por: Sibum, Imco, et al.
Publicado: (2019)

Correction to: Patients’ usability of seven most used dry-powder inhalers in COPD
por: Dal Negro, Roberto W., et al.
Publicado: (2019)

Clinical recommendations for dry powder inhaler use in the management of COPD in primary care
por: Leving, Marika T., et al.
Publicado: (2022)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

Understanding Carrier Performance in Low-Dose Dry Powder Inhalation: An In Vitro–In Silico Approach
por: Pinto, Joana T., et al.
Publicado: (2021)

Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers
por: Lexmond, Anne J., et al.
Publicado: (2014)

Higher lung deposition with Respimat(®) Soft Mist(™) Inhaler than HFA-MDI in COPD patients with poor technique
por: Brand, Peter, et al.
Publicado: (2008)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)
por: Dekhuijzen, Pieter Nicolaas Richard, et al.
Publicado: (2016)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial
por: Beeh, Kai-Michael, et al.
Publicado: (2021)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Development of High Dose Oseltamivir Phosphate Dry Powder for Inhalation Therapy in Viral Pneumonia
por: Aziz, Shahir, et al.
Publicado: (2020)

Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β(2)-agonist via dry-powder inhalers and pressurized metered-dose inhalers
por: Wittbrodt, Eric T, et al.
Publicado: (2018)

Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD
por: Caramori, Gaetano, et al.
Publicado: (2014)

Effect of compression pressure on inhalation grade lactose as carrier for dry powder inhalations
por: Raut, Neha Sureshrao, et al.
Publicado: (2016)

Appropriate use of a dry powder inhaler based on inhalation flow pattern
por: Kondo, Tetsuri, et al.
Publicado: (2017)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Understanding the Importance of Capsules in Dry Powder Inhalers
por: Buttini, Francesca, et al.
Publicado: (2021)

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders
por: Dalby, Richard N, et al.
Publicado: (2011)

Ease-of-use preference for the ELLIPTA(®) dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older
por: Komase, Yuko, et al.
Publicado: (2014)

Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations
por: Shepard, Kimberly B., et al.
Publicado: (2022)

Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers
por: Buttini, Francesca, et al.
Publicado: (2016)

Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers
por: Zhang, Tongtong, et al.
Publicado: (2018)

Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD
por: Chetta, Alfredo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s3k9jaf52o4is6d39g4si5eku4